Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 - Wikidata - awgldk - TriplyDB

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q34648079

about

Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes Evolution of proviral gp120 over the first year of HIV-1 subtype C infection Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys Appreciating HIV type 1 diversity: subtype differences in Env.Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility.HIV-1 envelope subregion length variation during disease progression Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.The cat and mouse of HIV-1 antibody escape.Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure.R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Characteristics of the earliest cross-neutralizing antibody response to HIV-1.The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies.B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.Phenotypic properties of transmitted founder HIV-1 Specificity of the autologous neutralizing antibody response Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease.

P2860

Q21245045-CA5AE62C-747F-4621-8AE9-A2778C7B3CFF Q24612992-C6FFD34E-D4CD-44D8-AF18-9DBBD004B42D Q24653373-83C123D0-6B11-4535-8BEE-F9AD5746502A Q27676728-EB9E07B3-07F2-4BD4-BA50-16241DC05789 Q28483205-02463CE7-2EE6-4F64-B87B-BE240E2FD64A Q28487168-90276A4B-FCF7-4FCF-A932-57C6BC415518 Q28751926-48D96C97-1D4C-437B-95D4-C2625873A0F8 Q30372757-3517ADE4-DE45-408F-9FF8-6B27B99C0FA8 Q30375834-A3E7B437-9DF0-472E-8901-5F545078ECFD Q30376421-041C9FBD-42B0-4AC7-944E-0F5C32CB76E5 Q30397933-EBC68570-E31D-4B3D-8555-DB41048A15BB Q33392865-08433C25-D913-40A6-B804-BB581B94D594 Q33504599-8A196F92-5768-46BE-9419-502F7FE93B6E Q33504604-16A784A7-C9E9-4528-A026-F402554AD57D Q33504607-A958CAA2-7AAC-48D8-BF9B-BAAD15128C70 Q33606936-78BAA6C9-F522-4E72-B95F-CDDE0A6F9EAE Q33640144-F31F0F8B-11F0-453E-A0E1-3E3C0BAB90CC Q33648910-A02F85DC-C90A-421D-88E0-47920AE7C9D1 Q33664910-048D4EFD-40EC-4351-9545-E97F1303F5AC Q33719511-04DC345A-6D07-4904-8FA4-DF60F4A31A44 Q33798076-F1C2CA2F-8812-46E0-9329-A1F4EE79DFE6 Q33839456-49DED5E1-DDD6-4709-A66E-4DA52F23F646 Q33873719-BF8B4ECF-98AD-46A3-BD6B-AEAD0B318E66 Q33877434-0E9F008B-CA7C-46D7-A0BD-723A21887E5E Q34008741-B8B8A7DA-38AF-4D55-940F-789311F84E45 Q34083235-DFDE3DB2-26DD-4E27-8A6F-8A7B1C987F8F Q34203163-DECF2F97-7A1B-4424-8C05-5E5BDE5FF0DC Q34336058-09C23319-062D-48AB-89DA-CD1470A46272 Q34415389-B18B3397-27FF-4289-A467-2C64CD31E2FF Q34455457-7CE2645E-62F5-483F-806D-EB46CBC979A5 Q34463861-A626770F-5A57-44B4-BDFF-8AE716DFF9D9 Q34478071-0F520AD1-FB03-45F5-B3CA-8C04F97D862D Q34485260-F0E214E2-5BBE-4B15-8EC7-CAFA1B67BF05 Q34742533-870512DC-CDA3-4B4E-9706-C1A28981CAEE Q34819651-206E4818-5BEB-40BE-BCF8-725896AC37A8 Q34874985-4A113B27-E52E-4A04-972D-A7424CAEB68A Q35034268-400211C1-C2C1-4F3D-ADFB-9833845AC6FE Q35076717-8819839B-373D-4C30-8213-D4F790AB04BA Q35077483-3810DD7A-3715-42D7-AAFA-275811009417 Q35127401-435F3FFE-78FE-48BB-B3DA-5721239FBB4E

P2860

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q34648079

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Evidence for potent autologous ...... immunodeficiency virus type 1

@ast

Evidence for potent autologous ...... immunodeficiency virus type 1

@en

Evidence for potent autologous ...... immunodeficiency virus type 1

@nl

type

label

Evidence for potent autologous ...... immunodeficiency virus type 1

@ast

Evidence for potent autologous ...... immunodeficiency virus type 1

@en

Evidence for potent autologous ...... immunodeficiency virus type 1

@nl

prefLabel

Evidence for potent autologous ...... immunodeficiency virus type 1

@ast

Evidence for potent autologous ...... immunodeficiency virus type 1

@en

Evidence for potent autologous ...... immunodeficiency virus type 1

@nl

P1433

Q34648079-BB60B333-DE7D-4A80-A5B9-0B92D3D2271B

P1476

Q34648079-1F96BE43-C8AC-4527-BD4F-57736A54AE50

P2093

Q34648079-2E5E188A-4324-42E3-BB72-0638334DDFD1

Q34648079-38554EB7-DE92-473C-BC08-C1D3226D742D

Q34648079-5C94388E-D56D-4925-97DC-65AE46553E8F

Q34648079-63CF8163-E629-4A19-A5AA-445FF036842D

Q34648079-90FC9B78-0249-47AC-9D8B-894940C4FE33

Q34648079-92B391C5-5DE7-44D5-8BB5-9FD273A9BB2C

Q34648079-C728E7D9-2946-4E1F-BC01-ED90FDF4911B

Q34648079-C8C3C8DE-37BA-4A98-8CCF-9EF28714C539

Q34648079-E8BEC779-32E7-4752-A92D-10A588A4ED04

P2860

Q34648079-0E8ECDFA-B183-45BE-A580-119E4F493F65

Q34648079-0EDC0501-6F05-424F-B468-BD013546C1CA

Q34648079-274F2FCB-C67C-45FB-B5DC-D4F1BFF7B2E0

Q34648079-3F652EF0-BC62-402A-9DB0-7876C67ABD09

Q34648079-4402DE45-1F45-4185-ACD5-1D2A6169BB52

Q34648079-5373BC01-3C9F-483D-AA68-9834C6435171

Q34648079-60D9A051-C82F-4B07-AD48-81765CD28BE8

Q34648079-676F3272-783F-42FD-9058-3290886A41E2

Q34648079-68343CBC-BB17-432D-95F5-A7C4E254291F

Q34648079-7DB90279-BBAE-47F2-8A11-180F63A5AFBA

P304

Q34648079-163399DB-7D69-4AF2-975F-DF26F66CC8A1

P31

Q34648079-E4C7ACEF-A621-4811-860D-0DCC70275749

P356

Q34648079-8B5522BC-2C1F-4CA8-B7D6-37452B65A06E

P407

Q34648079-A0B3A489-1E5E-43B0-A563-8F405D3B6492

P433

Q34648079-60D6A5A1-D9A7-458E-9DF2-8ADF20F8A0D4

P478

Q34648079-9EF383E3-1F6E-4C44-81A0-CA40CC65175E

P50

Q34648079-1C24F57E-E0B4-448E-B260-8A03714A0ADE

Q34648079-7F91B5C9-02E0-4048-A53A-58FC9CD62439

Q34648079-A190EF08-BB26-4884-9E80-CB58459A9D74

P577

Q34648079-9EF1A31E-B1ED-400E-9321-CB5532C311B4

P5875

Q34648079-3E176AE1-6F9D-4741-88D7-5285581AD0DF

P698

Q34648079-9B7299C0-3615-4277-A823-7348E0A349E7

P921

Q34648079-A91DE391-CFF8-4D57-B706-F94E605CFC28

P932

Q34648079-166E2D84-9FA1-438B-8FE1-83E42CFD6C0E

P356

P1433

Journal of Virology

P1476

Evidence for potent autologous ...... immunodeficiency virus type 1

@en

P2093

Bing Li

http://www.w3.org/2001/XMLSchema#string

Cynthia A Derdeyn

http://www.w3.org/2001/XMLSchema#string

Eric Hunter

http://www.w3.org/2001/XMLSchema#string

Jerry L Blackwell

http://www.w3.org/2001/XMLSchema#string

Joseph Mulenga

http://www.w3.org/2001/XMLSchema#string

Julie M Decker

http://www.w3.org/2001/XMLSchema#string

Roy W Johnson

http://www.w3.org/2001/XMLSchema#string

Susan Allen

http://www.w3.org/2001/XMLSchema#string

Xiping Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

Antibody neutralization and escape by HIV-1

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa.

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.

P304

5211-5218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00201-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Frederic Bibollet-Ruche

Beatrice H. Hahn

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7082478

http://www.w3.org/2001/XMLSchema#string

P698

16699001

http://www.w3.org/2001/XMLSchema#string

P921

P932

1472127

http://www.w3.org/2001/XMLSchema#string